ETON logo

ETON Eton Pharmaceuticals, Inc.

NASDAQ · Drug Manufacturers - Specialty & Generic · Healthcare

$63.93
+2.48 (+4.04%)

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N…

Market Cap: $1.84Bwww.etonpharma.com

Price

No data yet.

Social Signal Score

59
5d
70
1 mentions
—
30d
59
8 mentions
—
60d
54
11 mentions
—
90d
53
12 mentions
—
news: 12

Analyst Ratings

7 analysts
Buyconsensus
Strong Buy 0Buy 7Hold 0Sell 0Strong Sell 0
Avg price target$72+12.6%
Low $68Median $70High $78
Current Consensus

Revenue

$57.92M
$-161.0K$19.20M$38.56M$57.92M
Jun 2017Sep 2026

Analyst Estimates

FY2025
$0.37
$0.27–$0.47
2 analysts
FY2026
$2.01+443% YoY
$1.54–$2.48
2 analysts
FY2027
$2.90+44% YoY
$2.04–$3.75
2 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Sean E. Brynjelsen
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
44
Beta
0.83
Country
US
Piotroski score
6 / 9 (Middling)
Altman Z-score
17.21
www.etonpharma.com